Company

Trillium Therapeutics Inc.

Headquarters: Mississauga, ON, Canada

TSX: TRIL +0.52%

Market Cap

C$2.30 Billion

CAD as of Nov. 1, 2021

US$1.82 Billion

Market Cap History

Trillium Therapeutics Inc. market capitalization over time

Evolution of Trillium Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Trillium Therapeutics Inc.

Detailed Description

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Trillium Therapeutics Inc. has the following listings and related stock indices.


Stock: TSX: TRIL wb_incandescent

Stock: NASDAQ: TRIL wb_incandescent

Stock: FSX: R5WP wb_incandescent

Details

Headquarters:

2488 Dunwin Drive

Mississauga, ON L5L 1J9

Canada

Phone: 416 595 0627